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Clinical correlates of blood-derived
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Abstract
Background: Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain
dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation
sequencing technologies. Herein, we investigated the clinical utility of circulating tumor DNA (ctDNA) (the liquid
biopsy) in this malignancy.
Methods: ctDNA was analyzed in 112 patients with PDAC (54–73 genes) and tissue DNA in 66 patients (315 genes)
(both clinical-grade next-generation sequencing). Number of alterations, %ctDNA, concordance between ctDNA
and tissue DNA, and correlation of ctDNA results with survival were assessed.
Results: The most common genes altered in ctDNA were TP53 (46% of patients, N = 51) and KRAS (44%, N = 49).
Median number of characterized ctDNA alterations per patient was 1 (range, 0–6), but patients with advanced
PDAC had significantly higher numbers of ctDNA alterations than those with surgically resectable disease (median,
2 versus 0.5, P = 0.04). Overall, 75% (70/94) of advanced tumors had ≥ 1 ctDNA alteration. Concordance rate between
ctDNA and tissue DNA alterations was 61% for TP53 and 52% for KRAS. Concordance for KRAS alterations between
ctDNA and tissue DNA from metastatic sites was significantly higher than between ctDNA and primary tumor DNA
(72% vs 39%, P = 0.01). Importantly, higher levels of total %ctDNA were an independent prognostic factor for worse
survival (hazard ratio, 4.35; 95% confidence interval, 1.85–10.24 [multivariate, P = 0.001]). A patient with three ctDNA
alterations affecting the MEK pathway (GNAS, KRAS, and NF1) attained a response to trametinib monotherapy ongoing
at 6months.
Conclusions: Our findings showed that ctDNA often harbored unique alterations some of which may be targetable
and that significantly greater numbers of ctDNA alterations occur in advanced versus resectable disease. Furthermore,
higher ctDNA levels were a poor prognostic factor for survival.
Keywords: Pancreatic cancer, Next-generation sequencing, Circulating tumor DNA, KRAS, Molecular oncology, Targeted
therapy
Introduction
In the USA, there are approximately 56,770 people
newly diagnosed with pancreatic cancer in 2019, with
high mortality (~ 46,000 deaths) [1–3] .Although the
mortality from other types of gastrointestinal cancer,
such as gastric or colorectal cancers, are declining over
the past two decades, mortality from pancreatic cancer
has not declined [1]. It is estimated that pancreatic can-
cer will become the second cause of cancer death by
2030 [2].
The majority of pancreatic cancers (80–90%) are classi-
fied as pancreatic ductal adenocarcinomas (PDACs) [3].
One of the underlying reasons for high mortality associ-
ated with PDACs is that most patients have late-stage dis-
ease at the time of diagnosis. In fact, only 15–20% of
patients are considered to be surgical candidates at the
diagnosis [4]. Furthermore, prognosis even among patients
who were able to have surgery with negative margins
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remains poor (5-year survival rate was only 10–25% with
the median survival between 10-20months) [5, 6].
Multi-agent systemic chemotherapies with regimens of
5-fluorouracil, leucovorin, irinotecan, and oxaliplatin
(FOLFIRINOX) and gemcitabine plus nab-paclitaxel
have shown improved survival over single-agent gemci-
tabine and have become standard treatment options for
metastatic PDACs [7, 8]. However, median progression-
free survival (PFS) and overall survival (OS) remain dis-
mal (PFS: FOLFIRINOX, 6.4 months; gemcitabine plus
nab-paclitaxel, 5.5 months, gemcitabine alone, 3.3–3.7
months; OS: FOLFIRINOX, 11.1 months; gemcitabine
plus nab-paclitaxel, 8.5 months, gemcitabine alone, 6.7–
6.8 months) [7, 8]. Therefore, along with the recent de-
velopment in sequencing technology, a personalized,
molecular-targeted approach for PDAC is becoming an
active area of research [9]. Several case studies showed a
benefit of platinum-based chemotherapies or poly ADP-
ribose polymerase (PARP) inhibitors for PDAC patients
with BRCA1/2 abnormalities, and the NCCN guidelines
suggest consideration of platinum-based regimen as a
first-line therapy for advanced-stage pancreatic cancer
patients with BRCA gene mutations [10–14].
Although molecular analysis on tissue samples is
generally attempted, its clinical utility is often dimin-
ished in pancreatic cancer due to the difficulty in
obtaining tissue with adequate quality for comprehen-
sive molecular testing [15]. Furthermore, tumor het-
erogeneity may challenge small biopsies, particularly
in metastatic disease with multiple tumors [16]. In
contrast, the utility of plasma-derived circulating
tumor DNA (ctDNA) has recently been assessed in
several tumor types [17–21]. ctDNA has some advan-
tages over tissue DNA analysis: (1) readily available,
(2) less-invasive, (3) potential real-time monitoring of
disease status or treatment response, and (4) may re-
flect shed DNA from multiple metastatic sites [22–
24]. On the other hand, the small amount of tumor
DNA in the circulation results in limitations as well.
Herein, we assessed the genomic landscape of ctDNA
in patients with PDAC, using clinical-grade next-
generation sequencing (NGS). We investigated the clin-
ical implications of the findings including concordance
between tissue and blood DNA sequencing, relationship
between ctDNA findings and survival, and potential as
well as actual actionability, with the latter illustrated by
a patient with multiple alterations affecting the MEK
pathway whose tumor responded to the MEK inhibitor
trametinib.
Materials and methods
Study population
We reviewed the clinicopathological and genomic infor-
mation of 112 consecutive eligible patients with PDAC
who had a blood-derived ctDNA evaluation. Only pa-
tients with pathologically proven PDAC were included.
All investigations followed the guidelines of the Univer-
sity of California San Diego Moores Cancer Center In-
ternal Review Board and were performed in accordance
with the Declaration of Helsinki under the auspices of
our approved study Profile-Related Evidence Determin-
ing Individualized Cancer Therapy study (PREDICT
study, NCT02478931) and any investigational therapy
for which the patients gave consent [25].
Circulating tumor DNA (ctDNA) and tissue DNA
sequencing
ctDNA NGS
All blood samples for ctDNA were evaluated at a clinical
laboratory improvement amendments (CLIA) licensed
and College of American Pathologist (CAP) accredited
clinical laboratory, Guardant Health, Inc. (Redwood
City, CA. http://www.guardanthealth.com). Blood
samples were collected in 10ml Streck tubes, and 5 to
30 ng of ctDNA was used for sequencing as previously
described [26]. The ctDNA assay can sequence cancer-
associated genes to identify somatic alterations with high
analytic sensitivity, which reaches detection of 1–2 single
mutant fragments from a 10-mL blood sample (0.1%
limit of detection) and high specificity (> 99.9999%) (54
to 73 genes, Additional file 1: Table S1). Only character-
ized genomic alterations were used for analysis (syn-
onymous alterations or variants of unknown significance
were excluded). Mutant allele frequency (%ctDNA) was
calculated as the number of mutant molecules divided
by the total number of DNA fragments in each mutated
gene. Percent ctDNA could not be calculated for gene
amplifications. This study considered %ctDNA for only
characterized alterations and used median value as a cut-
off for maximum %ctDNA (of any alteration in a patient)
or total %ctDNA (evaluating all alterations per patient).
Tissue DNA NGS
All tissue DNA analyses in this study were performed by
a CLIA-licensed and CAP-accredited laboratory, Foun-
dation Medicine, Inc. (Cambridge, MA. https://www.
foundationmedicine.com). The sequencing was designed
to include all genes somatically altered in human solid
malignancies that were validated as targets for therapy,
either approved or in clinical trials, and/or that were un-
ambiguous drivers of oncogenesis based on available
knowledge. The assay interrogated 315 genes [27, 28].
Actionable alterations in ctDNA
This study assessed actionability for each genomic
alteration in ctDNA. We defined a characterized al-
teration as potentially druggable if it (or its pathway
signal) could be impacted at low inhibitory
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concentrations for small molecule inhibitors or if an
antibody specific to the protein product of the alter-
ation impacted it. Only cognate agents approved by
the US. Food and Drug Administration (FDA) (on- or
off-label use) or compounds that are currently in clin-
ical trials were considered (Additional file 1: Table
S2).
Outcomes and statistics
The continuous variables (described with median value and
range) and categorical variables (described with frequency
and percentage) were compared with the Mann-Whitney U
test and Fisher’s exact test, respectively. In terms of ctDNA
results according to disease stage, we compared metastatic,
locally advanced, or recurrent (abbreviated as “advanced”)
disease setting with surgical resectable cases whose blood
was biopsied before radical surgery. Concordance of gen-
omic alterations between ctDNA and tissue DNA was
assessed by concordance rate with Kappa value. Kappa
value is interpreted by commonly used agreement categor-
ies: 1 (perfect agreement) to 0 (no agreement other than
would be expected by chance). Most common gene
aberrations (altered in ≥ 8 samples) were used for concord-
ance analysis. When patients were stratified according by
tissue biopsy site or time interval between blood draw for
ctDNA and tissue biopsy, the difference in concordance
rate was compared by Fisher’s exact test. OS time was mea-
sured from date of blood draw for ctDNA to date of last
follow-up or all-cause death. In order to explore independ-
ent prognostic factors for the OS, we used Cox’s propor-
tional hazard model in multivariate analysis to estimate
hazard ratio (HR) with 95% confidence interval (CI). Vari-
ables with P < 0.1 in the univariate analyses (using the log-
rank test) were entered into the multivariate analysis. RO
performed and verified statistical analysis using SPSS ver-
sion 24 software (IBM Corporation, Armonk, NY).
Results
Genomic alterations in ctDNA for PDAC
A total of 112 patients with PDAC were evaluated for
ctDNA. Among them, 94 patients (84%) were analyzed
in the advanced setting, while 18 patients (16%) were an-
alyzed before (N = 10) or after radical surgery (N = 8)
for lesions that were surgically resectable at the time of
Table 1 Patient characteristics and number of genomic alterations detected in ctDNA among pancreatic ductal adenocarcinoma
patients (N = 112)
Characteristics for all patients [N = 112] N (%)
Median age (range) (years)* 67.8 (38.0–92.7)
Gender
Men 60 (53.6%)
Women 52 (46.4%)
Ethnicity
Caucasian 76 (67.9%)
Hispanic 16 (14.3%)
Asian 7 (6.3%)
African American 4 (3.6%)
Other/unknown 9 (8.0%)
Disease status at the time of blood draw
Advanced (metastatic, locally advanced or recurrent disease) 94 (83.9%)
Preoperative (surgically resectable, blood obtained before surgery) 10 (8.9%)
Postoperative (surgically resectable, blood obtained after surgery) 8 (7.1%)
Number of patients with ≥ 1 characterized alteration 78 (69.6%)
Median number of characterized alterations per patient (range) 1 (0–6)
Comparisons of ctDNA results between advanced cases and preoperative cases**
Parameters Advanced cases (N = 94) Preoperative cases (N = 10) P value
Number of characterized alterations per patient (range), median (range) (%) 2 (0–6) 0.5 (0–3) 0.04
No. of patients with detectable characterized alterations 70 (74.5%) 5 (50.0%) 0.14
Maximum %ctDNA per patient (characterized alterations), median (range) (%) 0.4 (0.0–64.6) 0.0 (0.0–0.62) 0.02
Total %ctDNA per patient (characterized alterations), median (range) (%) 0.6 (0.0 - 92.05) 0.0 (0.0 - 0.70) 0.007
*Age at date of advanced disease diagnosis or date of first diagnosis for surgically resectable diseases
**Postoperative cases (blood obtained after radical surgery) were not included in these comparisons
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blood draw for ctDNA (Table 1). Of the 112 patients,
70% (N = 78) had ≥ 1 characterized alteration in ctDNA,
and the median number of characterized alterations per
patient was 1 (range, 0 to 6). A total of 194 characterized
alterations were identified, including 158 amino acid
substitutions or frameshift mutations (81%), 35 gene am-
plifications (18%), and 1 gene deletion (0.5%). These
characterized alterations occurred in 29 different genes
and included 112 distinct alterations. The most common
genes altered were TP53 (46% of patients, N = 51), KRAS
(44%, N = 49), CDKN2A (7%, N = 8), and GNAS (7%, N
= 8) (Fig. 1).
Most patients had ctDNA alterations that were potentially
pharmacologically tractable
Overall, 90% of the characterized alterations (175/194)
in ctDNA were potentially targetable with FDA-
approved agents (on- or off-label use), and an additional
3% (6/194) were theoretically targetable with therapies
that are currently in clinical trials (Additional file 1:
Table S2). Meanwhile, 68% (N = 76) of the 112 patients
had ≥ 1 theoretically actionable alterations by an FDA-
approved agent (on- or off-label). Furthermore, among
the 94 patients with advanced PDAC, 73% (N = 69) had
≥ 1 theoretically actionable alteration by FDA-approved
agents (on- or off-label).
Patients with PDAC mostly had ctDNA portfolios that were
distinct at the molecular level despite common alterations
at the genomic level
Among the 78 patients who had ≥ 1 characterized alter-
ation, ID#60 and ID#88 (KRAS G12 V and KRAS ampli-
fication), ID#24 and ID#102 (TP53 V216M), ID#8 and
ID#85 (KRAS G12R), and ID#64 and ID#70 (KRAS G12
V) had molecularly identical portfolios in ctDNA. In
addition, two patients harbored alterations in TP53,
KRAS, and CDKN2A genes (ID#7 and ID#51), and 10
patients harbored alterations in TP53 and KRAS genes
(ID#3, ID#14, ID#31, ID#74, ID#76, ID#87, ID#95,
ID#96, ID#101, and ID#108), reflecting genomic portfo-
lios that were identical but alterations at the level of the
locus that were different (Additional file 1: Table S3).
Patients with advanced PDAC had more ctDNA alterations
and higher %ctDNA than those with surgically resectable
disease
When evaluated depending on disease stage at the time
of blood draw, median number of characterized alter-
ations per patient was significantly higher in the patients
with advanced PDAC (N = 94) than those with surgically
resectable disease (N = 10) (the blood for ctDNA was bi-
opsied before surgery) (2 versus 0.5, P = 0.04) (Table 1).
Overall, 75% of patients with advanced PDAC had ≥ 1
characterized alteration, compared with 50% of patients
Fig. 1 Frequency (% of patients) of characterized alterations in pancreatic ductal adenocarcinoma (ctDNA [N = 112] and tissue DNA [N = 66]).
Only genes altered in ≥ 2 patients were shown in tissue DNA
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with surgically resectable PDACs (P = 0.14). Moreover,
the maximum %ctDNA (among the characterized alter-
ations) per patient was significantly higher in the pa-
tients with advanced PDAC than those with surgically
resectable PDACs (median, 0.4 versus 0.0, P = 0.02), as
well as the total %ctDNA per patient (median, 0.6 versus
0.0, P = 0.007). Complete list of ctDNA alterations and
disease status at the time of ctDNA analysis for all the
patients was shown in Additional file 1: Table S4. When
comparing the ctDNA parameters according to disease
stage at the time of ctDNA analysis among the 94 pa-
tients with advanced PDAC (between patients with ≥ 1
treatment regimen prior to ctDNA test and chemother-
apy naïve), no significant differences were observed
(Additional file 1: Table S5).
Concordance of altered genes between ctDNA and tissue
DNA sequencing
Of the 112 patients, 66 patients (59%) also had tissue
DNA NGS analysis (Additional file 1: Figure S1). In tissue
DNA, alterations were commonly observed in KRAS, (91%
of the patients, N = 60), TP53 (77%, N = 51), and
CDKN2A/B (55%, N = 36) (Fig. 1). Among the 66 patients,
only four patients (6.1%) had genomically concordant re-
sults between ctDNA and tissue DNA (Additional file 1:
Table S6), and an additional 31 patients (47%) had
partially concordant results (having ≥ 1 identical gene mu-
tation) between the ctDNA and tissue sequencing.
Overall genomic concordance rate between ctDNA
and tissue DNA analyses was 61% for TP53 and 52% for
KRAS (Table 2). Although the alteration rate in
CDKN2A was 7% (N = 8 of 112 samples) in ctDNA ver-
sus 55% (N = 36 of 66 samples) in tissue (Fig. 1), this
discrepancy might be attributable to the fact that earlier
versions of the ctDNA panel did not assess allelic loss in
this gene; hence concordance rate was not assessable for
the CDKN2A gene.
Spatial and temporal effects on concordance
When compared according to tissue biopsy site (primary
tumor versus metastatic sites), the concordance rate for
KRAS was significantly higher between ctDNA and
metastatic sites than between ctDNA and primary tumor
(72% versus 39%, P = 0.01); the difference for TP53 was
not significant (Table 2). When compared according to
the time interval between blood draw and tissue biopsy,
the concordance rates for TP53 and KRAS genes were
numerically higher in patients with ≤ 6 months of time
interval than those with > 6 months (55–65% versus 41–
47%, but not statistically significant). Furthermore, con-
sistent concordance rates for TP53 and KRAS alterations
were observed among different ctDNA sequencing
panels (when we compared detection rates for TP53 and
KRAS alterations according to ctDNA panel [73-gene
panel, N = 41, versus 54–70-gene panels, N = 25], there
were no significant differences (P = 0.61 for TP53 and P
> 0.99 for KRAS alterations).
Overall survival from ctDNA analysis among patients with
advanced PDAC
Higher levels of ctDNA were associated with shorter
survival
Survival analysis included 94 patients with advanced
PDAC in whom the median follow-up time was 18.2
months (95% CI, 13.7–22.7). In the univariate analysis, the
presence of KRAS alterations in ctDNA and higher level
of total %ctDNA (≥ 0.6% [0.6% being the median %ctDNA
when total ctDNA was assessed]) were associated with
worse OS (Table 3 and Fig. 2). When the variables with P
value < 0.1 were entered into the multivariate analysis,
higher level of total %ctDNA (HR 4.35, 95% CI 1.85–
10.24) (P = 0.001) and ≥ 1 systemic therapy prior to
ctDNA analysis (HR 2.89, 95% CI 1.51–5.55) (P = 0.001)
were significantly associated with worse OS from ctDNA
analysis in PDAC (OS from advanced disease diagnosis
was also shorter in patients with higher level of total
%ctDNA) (Additional file 1: Figure S2). Even when the pa-
tients were stratified by ctDNA sequencing panel, there
was no major difference between the 73-gene panel and
the 54-70-gene panels (Additional file 1 Figure S3). Pres-
ence of KRAS or TP53 alteration in ctDNA was not sig-
nificantly associated with OS in the multivariate analysis.
ctDNA analysis and selection of targeted therapy
Among the 94 patients with advanced PDAC, only 8 pa-
tients had treatment initiated based on the ctDNA re-
sults, and one of these patients responded (13%). This
patient was unusual in that he had three alterations in
the MEK pathway (discussed below).
Patient ID#111
An 83-year-old man with a locally advanced PDAC pre-
sented with abdominal and back pain (Eastern Cooperative
Oncology Group Performance Status [ECOG-PS] = 2). His
CT scan showed a pancreatic body tumor (6.5 × 3.2 cm)
spreading to the retroperitoneum and encasing the aorta and
celiac artery and the dilation of the pancreatic duct. The bil-
iary obstruction was not observed. Unfortunately, tissue bi-
opsy of the pancreatic mass was insufficient for genomic
analysis. However, his blood-derived ctDNA revealed EGFR
G1022S, GNAS R201C, KRAS G12D, MTOR D258fs, and
NF1 D1976fs. Because of the patient’s age, he was hesitant to
undergo chemotherapy. Based on the ctDNA analysis, he
started the first-line treatment with trametinib (potentially
targeting GNAS, KRAS, and NF1 alterations (Additional file
1: Table S2) [29–34]. He tolerated this treatment well and
his pain significantly improved. Although his restaging CT
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was not evaluable due to inability to use iodine contrast
(underlying renal insufficiency), his PET-CT at 15weeks
showed only mild uptake in the primary tumor and CA19-9
demonstrated a remarkable decrease from 7272 to 1303U/
ml (normal upper limit is 42U/ml) (Fig. 3). Serial ctDNA
was analyzed at 19weeks after the initiation of treatment and
showed a decrease in %ctDNA for NF1, and EGFR, GNAS,
KRAS, and MTOR mutations were no longer detected (Fig.
3). The treatment continues at 26+ weeks with good
tolerance.
Discussion
Despite the recent development of aggressive chemo-
therapies, patients with pancreatic cancer, who are gen-
erally diagnosed with advanced stage disease, have a
dismal outcome. Therefore, improvement in treatment
strategies for this lethal malignancy based on a better
understanding of its biology is urgently needed. Here,
we investigated the landscape of ctDNA NGS in pancre-
atic cancer, its concordance with tissue DNA NGS, and
the clinical implications of the findings.
We found that 70% of patients with PDAC had ≥ 1
characterized genomic alteration in ctDNA (Table 1).
Importantly, among the 94 patients with advanced
PDAC, 73% (N = 69) had ≥ 1 theoretically actionable al-
teration by FDA-approved agents (on- or off-label)
(Additional file 1: Table S2), opening the doors for preci-
sion matching trials [35–37]. These observations may be
especially pertinent because several approved agents
(such as gemcitabine and erlotinib) have only a small
Table 2 Overall concordance between ctDNA and tissue DNA based on time interval between blood draw and tissue biopsy and
on whether primary or metastatic tumor was biopsied (N = 66)
Patients with pancreatic ductal adenocarcinoma who had both ctDNA and tissue DNA sequencing (N = 66)
Tissue DNA (+) Tissue DNA (−) Overall
concordance* (%)
Kappa (SE)
TP53 ctDNA
(+)
29 (44%) 4 (6.1%) 61 0.21 (0.1)
ctDNA
(−)
22 (33%) 11 (17%)
KRAS ctDNA
(+)
28 (42%) 0 (0.0%) 52 0.14 (0.1)
ctDNA
(−)
32 (48%) 6 (9.1%)
Concordance depending on whether primary tumor or metastatic site was biopsied
Primary tumor (n = 41) Metastatic sites (n = 25)
Tissue DNA
(+)
Tissue DNA
(−)
Overall
concordance* (%)
Kappa
(SE)
Tissue DNA (+) Tissue DNA
(−)
Overall
concordance* (%)
Kappa
(SE)
P
value
TP53 ctDNA
(+)
14 (34%) 1 (2.4%) 54 0.19
(0.1)
15 (60%) 3 (12%) 72 0.27
(0.2)
0.20
ctDNA
(−)
18 (44%) 8 (20%) 4 (16%) 3 (12%)
KRAS ctDNA
(+)
14 (34%) 0 (0.0%) 39 0.05
(0.04)
14 (56%) 0 (0.0%) 72 0.39
(0.2)
0.01
ctDNA
(−)
25 (61%) 2 (4.9%) 7 (28%) 4 (16%)
Concordance based on time interval between blood draw and tissue biopsy
≤ 6 months (n = 49) >6 months (n = 17)
Tissue DNA
(+)
Tissue DNA
(−)
Overall
concordance* (%)
Kappa
(SE)
Tissue DNA (+) Tissue DNA
(−)
Overall
concordance* (%)
Kappa
(SE)
P
value
TP53 ctDNA
(+)
25 (51%) 3 (6.1%) 65 0.24
(0.1)
4 (24%) 1 (5.9%) 47 0.10
(0.2)
0.25
ctDNA
(−)
14 (29%) 7 (14%) 8 (47%) 4 (24%)
KRAS ctDNA
(+)
22 (45%) 0 (0.0%) 55 0.17
(0.1)
6 (35%) 0 (0.0%) 41 0.07
(0.1)
0.40
ctDNA
(−)
22 (45%) 5 (10%) 10 (59%) 1 (6%)
*Genomic concordance was analyzed in this table rather than molecular locus concordance
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Table 3 Multivariate analysis for factors associated with overall survival from date of ctDNA analysis in patients with advanced PDAC
(N = 94)
Characteristics Univariate analysis Multivariate analysis*
Median OS months P value HR (95%CI) P value
Age
≥ 68 (N = 47) vs < 68 (N = 47) 11.5 vs 9.0 0.77 – –
Gender
Men (N = 51) vs women (N = 43) 9.9 vs 8.9 0.25 – –
Genomic alterations in ctDNA
KRAS (N = 48) vs not (N = 46) 7.5 vs 11.4 0.03 1.14 (0.53–2.45) 0.74
TP53 (N = 45) vs not (N = 49) 8.9 vs 10.1 0.67
Maximum %ctDNA**
≥ 0.4% (N = 49) vs < 0.4% (N = 45) 8.9 vs 11.4 0.17 – –
Total %ctDNA**
≥ 0.6% (N = 50) vs < 0.6% (N = 44) 6.3 vs 11.7 0.001 4.35 (1.85–10.24) 0.001
Number of characterized alterations
≥ 1 (N = 70) vs none (N = 24) 8.9 vs 11.4 0.27 – –
Number of systemic therapies prior to ctDNA analysis
≥ 1 regimen (N = 40) vs none (N = 54) 6.4 vs 9.9 0.09 2.89 (1.51–5.55) 0.001
Abbreviations: CI confidence interval, ctDNA circulating tumor DNA, HR hazard ratio; %ctDNA mutant allele frequency, OS overall survival
*Factors with P value < 0.1 in univariate analysis were included in the multivariate analysis
**Only characterized alterations were considered (synonymous alteration and VUS were excluded). Dichotomized at the median of 0.4% for the maximum
%ctDNA and 0.6% for the total %ctDNA
Fig. 2 Kaplan-Meier curve for overall survival from ctDNA analysis depending on total %ctDNA (characterized alterations only) dichotomized at
the median among patients with advanced pancreatic ductal adenocarcinoma (N = 94)
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impact on survival [38]. The weak clinical impact
may be due to lack of biomarker selection when pre-
scribing treatment or existence of multiple oncogenic
alterations. In fact, our data also showed that pa-
tients with advanced PDAC mostly had a unique
pattern of molecular portfolios in ctDNA (even when
the actual genomic alterations overlapped) and that
more than half of them (N = 48/94) had two or
more alterations, suggesting the need for a deep un-
derstanding of the effect of abnormalities in specific
gene loci [39]. For instance, KRAS is well known as
the dominant oncogene in pancreatic cancer and its
prevalence is generally over 90% [40, 41]. Consist-
ently, our data showed the prevalence of KRAS alter-
ations was 91% in tissue DNA NGS (Fig. 1).
Meanwhile, 9.1% (N = 6/66) of patients with ctDNA
and tissue DNA NGS had KRAS wild type in both of
the two tests (Table 2). Several previous reports have
suggested unique targetable alterations even in tu-
mors with KRAS wild type, such as EGFR exon 19
deletion and ERBB2 amplification [15, 42]. In our
series, among the six patients whose ctDNA and tis-
sue DNA NGS were both KRAS wild type, all had at
least one theoretically actionable alteration in both
the two tests, including EGFR amplification or
ERBB2 amplification.
Not unexpectedly, characterized alterations in ctDNA
were more frequent in patients with advanced PDAC
than in those with surgically resectable disease (median,
2 versus 0.5, P = 0.04); median of maximum %ctDNA
(0.4% versus 0%, P = 0.02) and median of total %ctDNA
(0.6% versus 0%, P = 0.007) were also higher (Table 1).
These findings are consistent with a previous report
showing that ctDNA was more easily detectable in
patients with metastatic cancer than those with localized
diseases [43, 44]. Higher tumor load presumably in-
creases ctDNA shedding to blood.
Overall concordance rate between ctDNA and tissue
DNA was 61% for TP53 anomalies and 52% for KRAS
alterations (Table 2). In this series, the frequency of
alterations in each gene was lower in ctDNA than in
tissue DNA (Fig. 1). It should be noted that the sensi-
tivity of ctDNA for tissue DNA in detecting alter-
ations was lower, compared with that of tissue DNA
for ctDNA (57% [29 of 51] versus 88% [29 of 33] for
TP53, and 47% [28 of 60] versus 100% [28 of 28] for
KRAS, respectively). Other studies have found similar
results [45–47]. Discordant cases that were positive in
tissue and negative in ctDNA have been previously
explained by low tumor load in surgically resectable
cases [43, 44]. In addition, detection of ctDNA can be
affected by systemic treatment prior to blood draw
[48, 49]. In terms of spatial effects on concordance,
we demonstrated that KRAS concordance was signifi-
cantly higher between ctDNA and metastatic sites than
between ctDNA and primary tumor (72% versus 39%, P
= 0.01) (Table 2). Consistent with our observations, a
prior study evaluating heterogeneity in ctDNA genomic
profiling results in gastroesophageal cancers also re-
ported that several targetable genomic alterations were
88% concordant between metastatic tissue and ctDNA
even when primary tumor and metastatic sites had dis-
cordant results [23]. The authors suggested that bio-
marker profiling of metastatic site tissue or ctDNA was
potentially more effective in selection of therapy than
interrogating primary sites. In fact, in this series,
ctDNA TP53 and KRAS alteration concordance rates in
the patients whose tissues were biopsied from
Fig. 3 A representative PDAC case who underwent a matched targeted therapy based on ctDNA analysis. An 83-year-old man treated with the
MEK inhibitor trametinib as single-agent therapy [ID#111]; he had alterations in GNAS, KRAS, and NF1, all of which can activate the MEK pathway.
The patient showed improvement in symptoms, CA19-9, and %ctDNA in the altered genes. CT scans with contrast could not be performed due
to renal insufficiency. Treatment is ongoing at 26+ weeks
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metastatic sites were numerically higher than the rates
in the patients whose tissues were biopsied from pri-
mary tumors (72% versus 54% for TP53, P = 0.20; 72%
versus 39% for KRAS, P = 0.01) (Table 2). (The rate of
tissue TP53 alterations was 76% [19 of 25] for meta-
static sites and 78% [32 of 41] for primary sites; for
KRAS alterations, it was 84% [21 of 25] versus 95% [39
of 41]; hence, there was no increased frequency of ei-
ther alteration in tissue from metastatic sites.) It is con-
ceivable that patients who have visible metastatic tumor
that can be biopsied for sequencing may have higher
tumor burden than those whose tissues for sequencing
were available only from primary tumor, and this may
explain the higher concordance rate with ctDNA. Fur-
ther investigation is required [47, 50, 51]. Somewhat
surprisingly, there was no statistically significant differ-
ence in concordance when ctDNA and tissue sampling
dates were ≤ 6 months versus > 6 months apart. To fur-
ther assess these spatial and temporal effects on con-
cordance, larger numbers of samples are required.
We also report that the total %ctDNA (dichoto-
mized at median %ctDNA) was associated with pa-
tient survival (median OS from blood draw for
ctDNA, 6.3 versus 11.7 months, P = 0.001; median OS
from advanced disease diagnosis: 10.8 versus 18.2
months, P = 0.03) (Fig. 2 and Additional file 1: Figure
S2). Several studies previously reported that the pres-
ence of detectable ctDNA was associated with poor
survival in pancreatic cancer [52, 53] or that the pres-
ence of KRAS alterations in ctDNA was a poor prog-
nostic marker for OS in advanced PDAC [52, 54, 55].
In our series, multivariate analysis showed that ≥1
prior therapy and higher total %ctDNA, the latter
perhaps reflecting greater tumor burden or shedding
potential, were independently associated with worse
OS (for higher total %ctDNA, HR, 4.35; 95%CI, 1.85–
10.24; multivariate P = 0.001) (Table 3). Also, the
presence of prior therapies (HR, 2.89; 95%CI, 1.51–
5.55; multivariate P = 0.001) may reflect refractory
cases who may have poorer prognosis.
To date, accumulating evidence has shown that matching
drugs to sequenced genomic alterations can be promising for
patients with advanced cancer [56–59]. However, we were
only able to match eight patients to therapy based on ctDNA
and only one (13%) showed salutary effects (Fig. 3). The pa-
tient is unusual in several ways. In general, it is known that
single targeted agents have limited effects in pancreatic can-
cer [31, 60, 61]. Tumor heterogeneity or the existence of co-
alterations may mediate resistance to scripted monotherapies
[62]. However, our patient had multiple alterations that could
activate the MEK pathway (GNAS R201C, KRAS G12D, and
NF1 D1976fs) [29–33] and demonstrated a remarkable re-
sponsiveness to the MEK inhibitor trametinib, with a steep
decline in CA19-9 and %ctDNA as well as improvement in
symptoms and PET imaging after therapy showing only min-
imal uptake in the tumor (Fig. 3). Our observation differs
from previous literature suggesting that MEK inhibitors lack
substantial anti-tumor activity among patients with pancre-
atic cancer [31, 63]. The salutary effects in our patient might
be due to the multiple MEK pathway abnormalities harbored
by his cancer.
Meanwhile, low target-drug matching rate in this series (8
of 94 patients with advanced PDAC) is a realistic challenge.
The remaining 55 patients received unmatched conventional
chemotherapies following the molecular profiling and 31 had
no systemic chemotherapies following the molecular profil-
ing (mostly due to clinical deterioration or continuation of
the regimen prior to the ctDNA test). Also, many patients
with pancreatic cancer have genomic alterations that are not
considered easily druggable. Therefore, to further investigate
the efficacy of matched targeted therapy approaches, im-
provement in drug or clinical trial access as well as ctDNA
testing in patients with less advanced disease will be
necessary.
In the NCCN guidelines (https://www.nccn.org), testing
for germline and somatic BRCA1/2 alterations is recom-
mended for selection of platinum-based chemotherapies or
PARP inhibitors based on emerging data from several small
studies [11, 12, 64–66]. In our series, the prevalence of
BRCA1/2 abnormalities in ctDNA and tissue DNA NGS
were 1.8% (N = 2/112; BRCA1 Splice Site SNV and BRCA2
T3033 fs) and 3.0% (N = 2/66; BRCA1 truncation intron 16
and BRCA2 A938fs*21), respectively (germline alterations
were not captured). Several genomic alterations are rare and
the number of patients who can benefit from targeting those
individual abnormalities is small, but further study to investi-
gate highly targetable biomarkers based on deep sequencing
can be justified.
This study has several limitations. First, the ctDNA gene
panel expanded with time, increasing from 54 to 73 genes
(Additional file 1: Table S1). Therefore, a limitation of the
study pertains to the fact that the sequencing panels were
different and so not all genes sequenced in tissue were se-
quenced in ctDNA. Nonetheless, our tissue and ctDNA
panels allowed the comparison of most of the commonly al-
tered genes in pancreatic cancer using clinical-grade assays
frequently utilized in patients. The discrepancy in the fre-
quency of CDKN2A/B loss between ctDNA and tissue (with
lower frequency in ctDNA) probably results from the fact
that its allelic loss was not captured in older panels of the
ctDNA sequencing. Second, not all patients had both ctDNA
and tissue DNA tests; therefore, future concordance analysis
should be performed with larger numbers of patients. More-
over, further analysis with tissue DNA from both primary tis-
sue and metastatic sites may help inform the issues related
to intratumoral heterogeneity (though in many patients with
pancreatic cancer, accessing biopsy sites can be challenging
or dangerous). Third, analysis of the influence of systemic
Patel et al. Journal of Hematology & Oncology          (2019) 12:130 Page 9 of 12
treatment on ctDNA alterations is not feasible in this study
due to the lack of serial ctDNA testing per patient. Finally,
additional studies are also needed to determine the impact of
matching ctDNA alterations to therapy beyond the eight pa-
tients matched in the current investigation.
Conclusions
The majority of patients with PDAC (70%) had at least one
characterized genomic alteration and over 40% had TP53 or
KRAS alterations in ctDNA (Table 1 and Fig. 1). Among pa-
tients with advanced PDAC, 73% had at least one alteration
that is potentially pharmacologically tractable by FDA-
approved agents. Patients with advanced PDAC had higher
numbers of characterized alterations and higher maximum
and total %ctDNA when compared to those with surgically
resectable diseases (Table 1). ctDNA results for KRAS muta-
tions were significantly more concordant with tissue DNA
when the biopsy was from a metastatic site (versus the pri-
mary site) (Table 2). Detection of higher levels of total
%ctDNA was an independent prognostic factor for poor
overall survival (Fig. 2 and Table 3). A unique patient with
three different alterations affecting the MEK pathway showed
a sustained response to the MEK inhibitor trametinib, indi-
cating that the nuances of how to best match patients to cog-
nate agents merit further study in PDAC.
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